As Congress pressures manufacturers to move biosimilars to market more quickly and the need for lower priced prescription drugs increases, there is a concern that public trust in the safety and efficacy of these new drugs could suffer.
However, PharmExec.com reported that a Sanford C. Bernstein financial analyst was optimistic that the biosimilars market will grow considerably over the next few years, particularly as regulatory issues are resolved. The analyst hopes that discounts will rise to more than 75% off the innovator price and “in the end, biosimilars may emerge as safer and more effective therapies than the innovator product due to the utilization of more advanced analytics and more efficient production systems.”
Stay tuned for more news from Big Molecule Watch.
